



# Edaravone in ALS: Additional Perspectives

18:30 – 20:00

Wednesday 15<sup>th</sup> May 2019

Auditorium Descartes

Vinci International Congress Centre, Tours

## Programme

---

### Welcome

**Markus Weber, MD**

Neuromuscular Diseases Unit/ALS Clinic; St Gallen; Switzerland

### Long-term Treatment Experience with Edaravone in ALS

**Hiide Yoshino, MD**

Director, Yoshino Neurology Clinic, Ichikawa, Japan

### The Revised El Escorial Criteria, Slow Progressors and Edaravone Trials

**Markus Weber, MD**

Neuromuscular Diseases Unit/ALS Clinic; St Gallen; Switzerland

### Effects of Edaravone on Clinical Stages in ALS

**Ammar Al-Chalabi, PhD FRCP DipStat**

King's MND Care and Research Centre; King's College London; UK

### Retention of Function; a detailed view of Edaravone clinical data

**Joseph Palumbo, MD**

Vice President, Medical Science and Translational Research (USA)

Fellow, Medical Sciences (Japan)

### Question and Answer Panel Discussion

**Faculty Panel**

---

#### **Edaravone does not have EU marketing authorisation.**

Edaravone is approved for the treatment of ALS in Japan, South Korea, USA, Canada, and Switzerland.

Registration conditions differ from country to country.

This Educational Symposium is sponsored by Mitsubishi Tanabe Pharma (MTPD).

---